146 related articles for article (PubMed ID: 37199601)
21. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
22. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the Hepatitis C Continua of Care Between Hepatitis C Virus/HIV Coinfected and Hepatitis C Virus Mono-Infected Patients in Two Treatment Eras During 2008-2015.
Roberson JL; Lagasca AM; Kan VL
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):148-155. PubMed ID: 28974107
[TBL] [Abstract][Full Text] [Related]
24. Contribution of alcohol use in HIV/hepatitis C virus co-infection to all-cause and cause-specific mortality: A collaboration of cohort studies.
Trickey A; Ingle SM; Boyd A; Gill MJ; Grabar S; Jarrin I; Obel N; Touloumi G; Zangerle R; Rauch A; Rentsch CT; Satre DD; Silverberg MJ; Bonnet F; Guest J; Burkholder G; Crane H; Teira R; Berenguer J; Wyen C; Abgrall S; Hessamfar M; Reiss P; d'Arminio Monforte A; McGinnis KA; Sterne JAC; Wittkop L;
J Viral Hepat; 2023 Sep; 30(9):775-786. PubMed ID: 37338017
[TBL] [Abstract][Full Text] [Related]
25. Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection.
Yin X; Kong L; Du P; Jung J
AIDS Care; 2022 Oct; 34(10):1330-1337. PubMed ID: 34581640
[TBL] [Abstract][Full Text] [Related]
26. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
[TBL] [Abstract][Full Text] [Related]
27. Survival of hepatitis C-infected haemophilia patients is predicted by presence of cirrhosis but not by anti-viral treatment.
Maor Y; Schapiro JM; Bashari D; Martinowitz U
Ann Hepatol; 2014; 13(6):753-61. PubMed ID: 25332261
[TBL] [Abstract][Full Text] [Related]
28. Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States.
Chen PH; Yenokyan K; Fojo AT; Hutton HE; Lesko CR; McCaul ME; Yang C; Cachay ER; Crane HM; Jacobson JM; Kim HN; Kitahata MM; Mayer KH; Moore RD; Napravnik S; Saag M; Lau B; Chander G
Drug Alcohol Depend; 2022 Dec; 241():109673. PubMed ID: 36332596
[TBL] [Abstract][Full Text] [Related]
29. HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015.
Radwan D; Cachay E; Falade-Nwulia O; Moore RD; Westergaard R; Mathews WC; Aberg J; Cheever L; Gebo KA;
J Acquir Immune Defic Syndr; 2019 Apr; 80(5):559-567. PubMed ID: 30649030
[TBL] [Abstract][Full Text] [Related]
30. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
[TBL] [Abstract][Full Text] [Related]
32. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
[TBL] [Abstract][Full Text] [Related]
33. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
[TBL] [Abstract][Full Text] [Related]
34. [Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients].
Ke YC; Li LH; Hu FY; Lan Y; He YZ; Chen XJ; Tang XP; Cai WP; Lu RC; He Y; Li HQ
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):282-287. PubMed ID: 29996340
[No Abstract] [Full Text] [Related]
35. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
36. The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences.
Fursa O; Mocroft A; Lazarus JV; Amele S; Lundgren J; Matulionyte R; Rasmussen LD; Rockstroh JK; Parczewski M; Jilich D; Moreno S; Vassilenko A; Lacombe K; Wandeler G; Borodulina E; Brännström J; Wiese L; Orkin C; Behrens GMN; Mansinho K; Portu JJ; Peters L;
AIDS; 2022 Mar; 36(3):423-435. PubMed ID: 34690281
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal.
Burgui C; San Miguel R; Goñi-Esarte S; Juanbeltz R; Úriz-Otano JI; Reparaz J; Sarobe M; Zozaya JM; Castilla J
Postgrad Med; 2023 May; 135(4):352-360. PubMed ID: 36305320
[TBL] [Abstract][Full Text] [Related]
38. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
39. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin.
Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA;
Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784
[TBL] [Abstract][Full Text] [Related]
40. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
